Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Unadjusted rates of mACR20/50/70 and mHAQ improvement

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Outcome, % Trimmed population Stratified-matched population
Rituximab Anti-TNF P value Rituximab Anti-TNF P value
(n = 265) (n = 737) (n = 205) (n = 205)
mACR20 36.6 28.7 0.02 38.1 22.0 0.001
mACR50 21.1 17.4 0.17 21.0 13.7 0.005
mACR70 10.2 8.8 0.46 10.2 7.3 0.29
mHAQ 33.2 24.2 0.004 34.2 23.9 0.02
  1. Anti-TNF anti–tumor necrosis factor, mACR modified American College of Rheumatology criteria, mHAQ modified Health Assessment Questionnaire